ClinicalTrials.gg
CompletedNCT04037943NUTSUpdated Aug 9, 2022

NUTS for the Prevention of Cardiovascular Disease in Chinese Adults

An interventional study of Walnuts 30 grams and Walnuts 60 grams in Cardiovascular Diseases and Dyslipidemias, sponsored by The George Institute for Global Health, China. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2022-08-09.

Sponsored by The George Institute for Global Health, China · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Sex
All
01

Study summary

This study evaluates the feasibility of walnuts supplementation among population of high CVD risks over a period of 6 months. 70 participants will be controls receiving non-edible gifts. 70 participants will be given 30 grams of walnuts everyday and 70 participants will be given 60 grams of walnuts a day.

Read the detailed description

Increased consumption of nuts improves the levels of lipid risk factors associated with cardiovascular disease and consistently relates to lower risk of cardiovascular disease (CVD) in prospective cohort studies. The estimates of health effects and potential population benefits of increased consumption of nuts are based mostly on observational data and there remains considerable uncertainty about whether higher intake of nuts will actually reduce cardiovascular outcomes. To address this uncertainty will require a well-conducted, adequately powered, large-scale, randomised control trial that tests the causal relationship between nut intake and the risk of cardiovascular diseases.

We hereby designed a 6-month walnut supplementation trial in a rural area of China with high rates of CVD, to obtain data to support and help to refine the design of a future long-term large RCT testing the effect of nut supplementation on CVD risk. The main objectives of the current trial are to assess the acceptability and adherence to two different doses of walnut supplementation (30 and 60 grams per day). The exploratory objectives are to determine the effects of walnut supplementation on cardiovascular risk factors including blood lipids, fasting glucose, and body weight.

02

Conditions studied

  • Cardiovascular Diseases
  • Dyslipidemias

Keywords

  • Alpha linolenic acid
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's enrollment of 210 is above the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

The George Institute for Global Health, China is the lead sponsor of 16 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A history of CVD, defined on the basis of a prior hospitalisation for a myocardial infarction or stroke, unstable angina, coronary artery bypass graft, percutaneous coronary intervention (with or without stenting), peripheral revascularization (angioplasty or surgery), symptomatic with documented hemodynamically-significant carotid or peripheral vascular disease, or amputation secondary to vascular disease, OR
  2. Male aged >60 years, or female aged>65 years, AND

With at least two of the following risk factors:

  1. Type 2 diabetes requiring treatment with at least two oral anti-hyperglycaemic agents and/or insulin
  2. Systolic blood pressure > 140 mmHg while on one or more antihypertensive agents
  3. Current daily smoking
  4. Dyslipidaemia defined as HDL-cholesterol\<1.0mmol/L or LDL-cholesterol>6.0mmol/L
  5. Micro or macro albuminuria

Exclusion criteria

Exclusion Criteria:

  1. Allergic to nuts (history of food allergy with to any of the components of nuts)
  2. Other serious medical condition that prevents nut consumption (e.g. digestive disease with fat intolerance)
  3. Any medical condition thought to limit survival to less than 1 year
  4. Difficulty with consuming nuts (e.g. dental health issues that prevent chewing walnuts)
  5. Unwilling to consume nuts
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Low-dose group

    Low-dose group will received 30 grams of walnuts everyday during the study period of 6 months.

    Dietary Supplement: Walnuts 30 grams

  • Experimental
    High-dose group

    High-dose group will received 60 grams of walnuts everyday during the study period of 6 months.

    Dietary Supplement: Walnuts 60 grams

  • No intervention
    Control group

    Control group will received non-edible gifts during the study period of 6 months.

Interventions

  • Dietary supplementWalnuts 30 grams

    Roasted walnuts without salt or sugar.

  • Dietary supplementWalnuts 60 grams

    Roasted walnuts without salt or sugar.

06

What researchers measure

Primary outcomes

  1. Post-intervention differences in blood plasma alpha linolenic acid between groups

    Blood plasma alpha linolenic acid will be measured at baseline and 6 months (end of trial).

    Time frame: From baseline to 6 months

Secondary outcomes

  1. Post-intervention differences in estimated dietary nuts intake from 24h dietary recall between groups

    Using 24 hour dietary recall to estimate dietary nuts intake at baseline and 6 months (end of trial).

    Time frame: From baseline to 6 months

  2. Differences in adherence and acceptability of walnuts between the high and low dose groups

    The adherence and acceptability of the supplement walnuts assessed by questionnaires conducted in the two intervention groups.

    Time frame: From 2 week, 12 weeks to 6 months

Other outcomes

  1. Post-intervention differences in plasma total triglycerides between groups

    Plasma total triglycerides (mg/dL) will be measured at baseline and 6 months.

    Time frame: From baseline to 6 months

  2. Post-intervention differences in plasma total cholesterol between groups

    Plasma total cholesterol (mg/dL) will be measured at baseline and 6 months.

    Time frame: From baseline to 6 months

  3. Post-intervention differences in plasma HDL- cholesterol between groups

    Plasma HDL- cholesterol (mg/dL) will be measured at baseline and 6 months.

    Time frame: From baseline to 6 months

  4. Post-intervention differences in plasma LDL- cholesterol between groups

    Plasma LDL- cholesterol (mg/dL) will be measured at baseline and 6 months.

    Time frame: From baseline to 6 months

  5. Post-intervention differences in blood glucose between groups

    Blood glucose will be measured at baseline and 6 months.

    Time frame: From baseline to 6 months

  6. Post-intervention differences in body weight between groups

    All participants' body weight will be measured at baseline and 6 months (end of trial) in kilograms.

    Time frame: From baseline to 6 months

07

Study locations

1 site
  • Yi Zhao
    Yinchuan, Ningxia 750004, China
08

References and documents

Publications

  • Liu Y, Li N, Yan N, Pan XF, Li Q, Micha R, Mozaffarian D, Huffman MD, Wang Y, Neal B, Tian M, Zhao Y, Wu JHY. Protocol for a randomized controlled trial to test the acceptability and adherence to 6-months of walnut supplementation in Chinese adults at high risk of cardiovascular disease. Nutr J. 2021 Jan 6;20(1):3. doi: 10.1186/s12937-020-00660-7. PubMed 33407490 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jul 2020, 9 months.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's 9 months is below that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2019
First posted
Jul 30, 2019
StartActual
Oct 14, 2019
Primary completionActual
Jul 30, 2020
CompletionActual
Dec 24, 2021
Last update
Aug 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04037943
Lead sponsor
The George Institute for Global Health, China
Collaborators
Ningxia Medical University
Responsible party
Sponsor
First posted
Jul 30, 2019
Start date
Oct 14, 2019
Primary completion
Jul 30, 2020
Completion
Dec 24, 2021
Last update
Aug 9, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion